Patrick Michael Round
Hoofd Techniek/Wetenschap/O&O bij NewAmsterdam Pharma BV
Actieve functies van Patrick Michael Round
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
NewAmsterdam Pharma BV
NewAmsterdam Pharma BV Pharmaceuticals: MajorHealth Technology NewAmsterdam Pharma BV develops novel drugs to treat dyslipidemia. It operates as a biotechnology company and develops anti-dyslipidemic compounds in cardiovascular disease indications. The firm's product DEZ-001 develops a potent cholesteryl ester transfer protein inhibitor that has shown a decrease of low-density lipoprotein levels, and an increase of high-density lipoprotein levels. The company was founded by John J. P. Kastelein in 2012 and is headquartered in Naarden, the Netherlands. | Hoofd Techniek/Wetenschap/O&O | - | - |
Xention Ltd.
Xention Ltd. Pharmaceuticals: MajorHealth Technology Part of Xention Pharma Ltd., Xention Ltd. is a British company that develops and researches drugs. The company is based in Newmarket, UK. Xention was founded in 2002. | Directeur/Bestuurslid | 17-05-2016 | - |
Forbion Capital Partners Management Holding BV
Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion Capital Partners Management Holding BV (Forbion) is a Netherlands-based venture capital firm which was founded by Bart Bergstein. Headquartered in Naarden, the firm specializes in late-stage and early-stage clinical development programs to optimize the commercial potential of their investee company's technologies. | Private Equity Investor | 01-01-2018 | - |
Loopbaan van Patrick Michael Round
Eerdere bekende functies van Patrick Michael Round
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
ario pharma Ltd.
ario pharma Ltd. Pharmaceuticals: MajorHealth Technology ario pharma Ltd. is a biopharmaceutical company, which engages in the development of drugs for the treatment of respiratory indications. The company was founded by John Ford and Patrick M. Round in 2010 and is headquartered in Great Shelford, the United Kingdom. | Hoofd Techniek/Wetenschap/O&O | 26-04-2011 | - |
Oprichter | - | - | |
Glaxo Wellcome Plc | Hoofd Techniek/Wetenschap/O&O | - | 28-06-2011 |
Corporate Officer/Principal | 28-06-2011 | - | |
Celltech R&D, Inc.
Celltech R&D, Inc. Drugstore ChainsRetail Trade Celltech R&D, Inc. provides research and development services for pharmaceutical products. The private company is based in Bothell, WA. | Corporate Officer/Principal | 17-02-2010 | - |
Xention Pharma Ltd.
Xention Pharma Ltd. Pharmaceuticals: MajorHealth Technology Xention Pharma Ltd. develops and researches drugs. The firm develops novel therapies for the treatment of atrial fibrillation; modulators of IKur and IKACh for atrial fibrillation. The company was founded by John W. Word and is headquartered in Newmarket, the United kingdom. | Hoofd Techniek/Wetenschap/O&O | 17-02-2010 | - |
Faculty of Pharmaceutical Medicine | Corporate Officer/Principal | - | - |
NOVO NORDISK A/S | Corporate Officer/Principal | - | - |
░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | - |
Opleiding van Patrick Michael Round
University of London | Undergraduate Degree |
Statistieken
Internationaal
Verenigd Koninkrijk | 8 |
Nederland | 3 |
Denemarken | 2 |
Operationeel
Corporate Officer/Principal | 5 |
Chief Tech/Sci/R&D Officer | 4 |
Undergraduate Degree | 1 |
Sectoraal
Health Technology | 8 |
Consumer Services | 2 |
Retail Trade | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
NOVO NORDISK A/S | Health Technology |
Bedrijven in privébezit | 9 |
---|---|
MedImmune Ltd.
MedImmune Ltd. BiotechnologyHealth Technology MedImmune Ltd. engages in research, development and exploitation of products in the field of molecular engineering. The company was founded on December 11, 1989 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
Faculty of Pharmaceutical Medicine | |
Xention Pharma Ltd.
Xention Pharma Ltd. Pharmaceuticals: MajorHealth Technology Xention Pharma Ltd. develops and researches drugs. The firm develops novel therapies for the treatment of atrial fibrillation; modulators of IKur and IKACh for atrial fibrillation. The company was founded by John W. Word and is headquartered in Newmarket, the United kingdom. | Health Technology |
Celltech R&D, Inc.
Celltech R&D, Inc. Drugstore ChainsRetail Trade Celltech R&D, Inc. provides research and development services for pharmaceutical products. The private company is based in Bothell, WA. | Retail Trade |
ario pharma Ltd.
ario pharma Ltd. Pharmaceuticals: MajorHealth Technology ario pharma Ltd. is a biopharmaceutical company, which engages in the development of drugs for the treatment of respiratory indications. The company was founded by John Ford and Patrick M. Round in 2010 and is headquartered in Great Shelford, the United Kingdom. | Health Technology |
Glaxo Wellcome Plc | Health Technology |
NewAmsterdam Pharma BV
NewAmsterdam Pharma BV Pharmaceuticals: MajorHealth Technology NewAmsterdam Pharma BV develops novel drugs to treat dyslipidemia. It operates as a biotechnology company and develops anti-dyslipidemic compounds in cardiovascular disease indications. The firm's product DEZ-001 develops a potent cholesteryl ester transfer protein inhibitor that has shown a decrease of low-density lipoprotein levels, and an increase of high-density lipoprotein levels. The company was founded by John J. P. Kastelein in 2012 and is headquartered in Naarden, the Netherlands. | Health Technology |
Xention Ltd.
Xention Ltd. Pharmaceuticals: MajorHealth Technology Part of Xention Pharma Ltd., Xention Ltd. is a British company that develops and researches drugs. The company is based in Newmarket, UK. Xention was founded in 2002. | Health Technology |
Forbion Capital Partners Management Holding BV
Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion Capital Partners Management Holding BV (Forbion) is a Netherlands-based venture capital firm which was founded by Bart Bergstein. Headquartered in Naarden, the firm specializes in late-stage and early-stage clinical development programs to optimize the commercial potential of their investee company's technologies. | Finance |